Watson Receives Clearance for Actavis Acquisition - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Watson Receives Clearance for Actavis Acquisition


ePT--the Electronic Newsletter of Pharmaceutical Technology

Watson Pharmaceuticals has received clearance from the Federal Trade Commission (FTC) for its acquisition of generic drug manufacturer Actavis. The $5.6-billion deal was first announced in April 2012, and will result in Watson becoming the third largest global generic-drug company.

The FTC identified 21 drugs either currently marketed or under development for which competition would be reduced as a result of the merger. The FTC’s consent order requires Watson or Actavis to sell assets related to 14 drugs to Par Pharmaceuticals. Watson has indicated in a press release that Par will acquire the following products:

  • Watson's morphine sulfate extended release capsules
  • Actavis' nifedipine extended release tablets
  • Actavis' metoclopramide hydrochloride tablets
  • Actavis' fentanyl transdermal film
  • Actavis' diltiazem hydrochloride extended release capsules
  • Watson's pending application for adapalene/benzoyl peroxide gel
  • Watson's pending application for oxymorphone hydrochloride ER tablets
  • Watson's pending application for amphetamine salts ER tablets
  • Actavis' pending application for rivastigmine patch
  • Actavis' pending application for glipizide extended release tablets
  • Actavis' pending application for varenicline tartrate tablets
  • Actavis' pending application for oxycodone hydrochloride extended release tablets
  • Actavis' pending application for ursodiol tablets

Sandoz, the generic pharmaceuticals division of Novartis, will acquire the following four products:

  • Actavis' bupropion hydrochloride 150-mg. extended release tablets
  • Actavis' lorazepam tablets
  • Actavis' diltiazem hydrochloride extended release capsules
  • Watson's pending application for dextromethorphan hydrobromide/quinidine sulfate

The FTC expects that Sandoz and Par will be able to replicate the competition that otherwise would have been lost through the acquisition. For the remaining three drugs, different steps have been taken to address the competition concerns. To remedy the FTC’s concerns related to one drug product, the combined firm is required to end Actavis’s existing development and manufacturing agreement with Pfizer and transfer the manufacturing rights back to Pfizer. For two other drugs, Watson and Actavis must relinquish the marketing rights to another firm.

According to the FTC press release, some products being divested have been identified by FDA as being in short supply. The FTC evaluated whether the proposed transaction would exacerbate any of those shortages, and concluded that the manufacture of those products would not likely be altered in a way that could affect their continued availability.

See related:

Watson Pharmaceuticals to Acquire Actavis for $5.6 Billion

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here